| A mechanistic model captures the emergence and implications of non-genetic heterogeneity and reversible drug resistance in ER+ breast cancer cells S Sahoo, A Mishra, H Kaur, K Hari, S Muralidharan, S Mandal, MK Jolly NAR cancer 3 (3), zcab027, 2021 | 63 | 2021 |
| Quantifying the patterns of metabolic plasticity and heterogeneity along the epithelial–hybrid–mesenchymal spectrum in cancer S Muralidharan, S Sahoo, A Saha, S Chandran, SS Majumdar, S Mandal, ... Biomolecules 12 (2), 297, 2022 | 21 | 2022 |
| PD-L1 activity is associated with partial EMT and metabolic reprogramming in carcinomas S Muralidharan, M Sehgal, R Soundharya, S Mandal, SS Majumdar, ... Current Oncology 29 (11), 8285-8301, 2022 | 17 | 2022 |
| Mapping phenotypic heterogeneity in melanoma onto the epithelial-hybrid-mesenchymal axis M Pillai, G Rajaram, P Thakur, N Agarwal, S Muralidharan, A Ray, ... Frontiers in Oncology 12, 913803, 2022 | 12 | 2022 |
| Characterizing heterogeneity along EMT and metabolic axes in colorectal cancer reveals underlying consensus molecular subtype-specific trends M Sehgal, S Ramu, JM Vaz, YR Ganapathy, S Muralidharan, ... Translational Oncology 40, 101845, 2024 | 4 | 2024 |
| Mapping phenotypic heterogeneity in melanoma on to the epithelial-hybrid-mesenchymal axis M Pillai, G Rajaram, P Thakur, N Agarwal, S Muralidharan, A Ray, ... bioRxiv, 2022 | | 2022 |
Mohit Kumar JollyAssociate Professor, Indian Institute of Science, Bangalore在 iisc.ac.in 的电子邮件经过验证
